Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed malignancy expressing GD2, including, but not limited to:

  • Medulloblastoma/primitive neuroectodermal tumor of the CNS
  • Malignant glioma
  • Neuroblastoma
  • Retinoblastoma
  • Ependymoma
  • Sarcoma
  • Melanoma
  • Small cell lung carcinoma
  • Other tumor types must have GD2 expression confirmed by immunohistochemical staining
• Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional therapy or for which no conventional therapy exists
• Prior measurable human anti-mouse monoclonal antibody titer allowed

PATIENT CHARACTERISTICS:

Age:

• 3 and over

Performance status:

• Not specified

Life expectancy:

• At least 2 months

Hematopoietic:

• Absolute neutrophil count greater than 1,000/mm^3
• Platelet count greater than 50,000/mm^3

Hepatic:

• Bilirubin less than 3 mg/dL

Renal:

• Creatinine less than 2 mg/dL
• Blood urea nitrogen less than 30 mg/dL

Other:

• May have active malignancy outside the central nervous system
• No obstructive hydrocephalus
• No CNS grade 3 or 4 toxicity as a consequence of prior treatments
• No life threatening infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Prior monoclonal antibody treatment allowed

Chemotherapy:

• Prior chemotherapy allowed
• Must have recovered from all hematopoietic and neurologic side effects of prior chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• Prior radiotherapy allowed
• At least 6 weeks since prior cranial or spinal irradiation

Surgery:

• Not specified